Flibanserin will be 'off the market within a few years' says Public Citizen adviser

The new “female Viagra” will be pulled from the market within years, according to the founder and senior adviser of Public Citizen’s Health Research Group, Sidney Wolfe.

In a statement released by health, safety and democracy activist group Public Citizen, he said that Addyi (flibanserin) from Sprout Therapeutics represents “serious dangers to women, with little benefit.” Dr Wolfe unsuccessfully urged the US Food and Drug Administration to reject flibanserin in June, as it had done in 2010 and 2013.

In the statement, he said: “It would not be surprising that after enough women have been seriously harmed by the “irreversible, or life threatening injuries” about which the FDA is concerned, flibanserin will have to be taken off the market. It is unconscionable that the FDA does not have the courage to prevent such damage from a drug with such a high ratio of risks to benefits.”